445 related articles for article (PubMed ID: 10486353)
1. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study.
Peters FT; Ganesh S; Kuipers EJ; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
Gut; 1999 Oct; 45(4):489-94. PubMed ID: 10486353
[TBL] [Abstract][Full Text] [Related]
2. Maximal acid reflux control for Barrett's oesophagus: feasible and effective.
Srinivasan R; Katz PO; Ramakrishnan A; Katzka DA; Vela MF; Castell DO
Aliment Pharmacol Ther; 2001 Apr; 15(4):519-24. PubMed ID: 11284781
[TBL] [Abstract][Full Text] [Related]
3. Acid suppression in the long-term treatment of peptic stricture and Barrett's oesophagus.
Lundell L
Digestion; 1992; 51 Suppl 1():49-58. PubMed ID: 1356869
[TBL] [Abstract][Full Text] [Related]
4. Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy.
Basu KK; Bale R; West KP; de Caestecker JS
Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1187-92. PubMed ID: 12439112
[TBL] [Abstract][Full Text] [Related]
5. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy.
Peters FT; Kuipers EJ; Ganesh S; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
Aliment Pharmacol Ther; 1999 Jul; 13(7):921-6. PubMed ID: 10383527
[TBL] [Abstract][Full Text] [Related]
6. Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus.
Sontag SJ; Schnell TG; Chejfec G; Kurucar C; Karpf J; Levine G
Aliment Pharmacol Ther; 1997 Feb; 11(1):147-56. PubMed ID: 9042987
[TBL] [Abstract][Full Text] [Related]
7. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus.
Cooper BT; Neumann CS; Cox MA; Iqbal TH
Aliment Pharmacol Ther; 1998 Sep; 12(9):893-7. PubMed ID: 9768533
[TBL] [Abstract][Full Text] [Related]
8. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results.
Van Laethem JL; Cremer M; Peny MO; Delhaye M; Devière J
Gut; 1998 Dec; 43(6):747-51. PubMed ID: 9824599
[TBL] [Abstract][Full Text] [Related]
9. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus.
Marshall RE; Anggiansah A; Manifold DK; Owen WA; Owen WJ
Gut; 1998 Nov; 43(5):603-6. PubMed ID: 9824338
[TBL] [Abstract][Full Text] [Related]
10. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Wani S; Sampliner RE; Weston AP; Mathur S; Hall M; Higbee A; Sharma P
Aliment Pharmacol Ther; 2005 Oct; 22(7):627-33. PubMed ID: 16181302
[TBL] [Abstract][Full Text] [Related]
11. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
Ortiz A; Martínez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
[TBL] [Abstract][Full Text] [Related]
12. Long term continuous omeprazole treatment of patients with Barrett's oesophagus.
Neumann CS; Iqbal TH; Cooper BT
Aliment Pharmacol Ther; 1995 Aug; 9(4):451-4. PubMed ID: 8527623
[TBL] [Abstract][Full Text] [Related]
13. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
Fitzgerald RC; di Pietro M; O'Donovan M; Maroni R; Muldrew B; Debiram-Beecham I; Gehrung M; Offman J; Tripathi M; Smith SG; Aigret B; Walter FM; Rubin G; ; Sasieni P
Lancet; 2020 Aug; 396(10247):333-344. PubMed ID: 32738955
[TBL] [Abstract][Full Text] [Related]
14. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus.
Todd JA; Basu KK; de Caestecker JS
Aliment Pharmacol Ther; 2005 Apr; 21(8):969-75. PubMed ID: 15813832
[TBL] [Abstract][Full Text] [Related]
15. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
16. Barrett's ulcer: response to standard dose ranitidine, high dose ranitidine, and omeprazole.
Lee FI; Isaacs PE
Am J Gastroenterol; 1988 Sep; 83(9):914-6. PubMed ID: 3414644
[TBL] [Abstract][Full Text] [Related]
17. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole.
Malesci A; Savarino V; Zentilin P; Belicchi M; Mela GS; Lapertosa G; Bocchia P; Ronchi G; Franceschi M
Gastrointest Endosc; 1996 Dec; 44(6):700-5. PubMed ID: 8979061
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial.
Ackroyd R; Brown NJ; Davis MF; Stephenson TJ; Marcus SL; Stoddard CJ; Johnson AG; Reed MW
Gut; 2000 Nov; 47(5):612-7. PubMed ID: 11034574
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and treatment of Barrett's oesophagus. A general survey.
Petrakis IE; Sciacca V; Iascone C
Acta Chir Belg; 2001; 101(2):53-8. PubMed ID: 11396051
[TBL] [Abstract][Full Text] [Related]
20. Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus.
Peters FT; Ganesh S; Kuipers EJ; Sluiter WJ; Karrenbeld A; de Jager-Krikken A; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
Scand J Gastroenterol; 2000 Dec; 35(12):1238-44. PubMed ID: 11199360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
